-
Mashup Score: 0Blood Pressure and Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction: DELIVER: - 2 year(s) ago
ABSTRACT Background Optimizing systolic blood pressure (SBP) in heart failure with preserved ejection fraction (HFpEF) carries a class I recommendation but with limited evidence. Sodium-glucose tra…
Source: JACC: Heart FailureCategories: Cardiac Surgery, Latest HeadlinesTweet
-
Mashup Score: 17Dapagliflozin in Patients Recently Hospitalized With Heart Failure and Mildly Reduced or Preserved Ejection Fraction: - 2 year(s) ago
Abstract Background Patients recently hospitalized for heart failure (HF) are at high risk for rehospitalization and death. Objectives The purpose of this study was to investigate clinical outcomes…
Categories: Cardiologists, Latest HeadlinesTweet-
#DELIVER 🔥 The consistent benefit of #dapa in pts recently (<_ 30 days) hospitalized for #HeartFailure #HFmrEF #HFpEF Even here “the sooner the better” 🍀 https://t.co/2o0PJRzezX @JJheart_doc @DrNasrien @PSJhund @mvaduganathan @DrMarthaGulati @mmamas1973 @gbiondizoccai @gcfmd https://t.co/FhveNcdLRC
-
-
Mashup Score: 2Dapagliflozin in Patients Recently Hospitalized With Heart Failure and Mildly Reduced or Preserved Ejection Fraction: - 2 year(s) ago
Abstract Background Patients recently hospitalized for heart failure (HF) are at high risk for rehospitalization and death. Objectives The purpose of this study was to investigate clinical outcomes…
Categories: Cardiologists, Latest HeadlinesTweet-
👆 #DELIVER 🔥 The consistent benefit of #dapa in pts recently (<_ 30 days) hospitalized for #HeartFailure #HFmrEF #HFpEF 👉 “Don’t delay start today” 👉 Not only major outcome but also #QoL 🍀 https://t.co/TAae2nJm8J @JACCJournals @nephondemand @MicheleSenni @morley_karina https://t.co/y3eMOkQqt4
-
-
Mashup Score: 8Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction | NEJM - 2 year(s) ago
Original Article from The New England Journal of Medicine — Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction
Source: New England Journal of MedicineCategories: Cardiologists, Latest HeadlinesTweet-
Delighted to discuss the results of the #Deliver trial of #Dapagliflozin in #HFmrEF #HFimpEF #HFpEF with @scottdsolomon at #ESCCongress. @radcliffeCARDIO Consistent results across SGLT2i trials & across range of #LVEF. We discussed pooled analyses too. https://t.co/n3AjDeLVce https://t.co/JQQskl6XA5 https://t.co/u4Q3Sq3OON
-
-
Mashup Score: 3Influence of NT-proBNP on Efficacy of Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction: - 2 year(s) ago
STRUCTURED ABSTRACT Background N-terminal pro-B-type natriuretic peptide (NT-proBNP) is used for diagnostic and prognostic evaluation in HF. Previous clinical trials in HF with mildly reduced or pr…
Source: JACC: Heart FailureCategories: Expert Picks, Latest HeadlinesTweet-
In this video, Drs. @pmyhre, @BiykemB, & @scottdsolomon talk about the influence of NT-proBNP on efficacy of #dapagliflozin in #HFmrEF/#HFpEF. 📃 #ESCCongress #JACCHF LBCT simpub paper: https://t.co/H4mIJdoY9i #CardioTwitter #ACCIntl https://t.co/nwGv1ZWvw2
-
-
Mashup Score: 0Dapagliflozin in Patients Recently Hospitalized With Heart Failure and Mildly Reduced or Preserved Ejection Fraction: - 2 year(s) ago
Abstract Background Patients recently hospitalized for heart failure (HF) are at high risk for rehospitalization and death. Objectives The purpose of this study was to investigate clinical outcomes…
Categories: Expert Picks, Latest HeadlinesTweet-
In this video, Dr. @JonWCunningham talks about #dapagliflozin in hospitalized or recently hospitalized #HFmrEF/#HFpEF patients in the #DELIVER trial. 📃 #ESCCongress #JACC LBCT simpub paper: https://t.co/QTuk2ROR6D #CardioTwitter #ACCIntl https://t.co/SfXQBIi6jo
-
-
Mashup Score: 11Estimated Event-Free Survival Benefits with Dapagliflozin in HF with Mildly Reduced or Preserved Ejection Fraction: - 2 year(s) ago
Abstract Background Recent guidelines support consideration of sodium glucose co-transporter(SGLT)-2 inhibitors in the long-term management of heart failure (HF) with mildly reduced or preserved ej…
Categories: Expert Picks, Latest HeadlinesTweet-
#ESCCongress #JACC LBCT SimPub: Modeling from the #DELIVER trial suggests #SGLT2i dapagliflozin may extend event-free survival by up to 2-2.5 years in #HFmrEF or #HFpEF. https://t.co/4WQYtjrblV #Dapagliflozin #CardioTwitter @mvaduganathan @scottdsolomon @UoGHeartFailure https://t.co/iFi7CVN8Rx
-
-
Mashup Score: 13Influence of NT-proBNP on Efficacy of Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction: - 2 year(s) ago
STRUCTURED ABSTRACT Background N-terminal pro-B-type natriuretic peptide (NT-proBNP) is used for diagnostic and prognostic evaluation in HF. Previous clinical trials in HF with mildly reduced or pr…
Source: JACC: Heart FailureCategories: Expert Picks, Latest HeadlinesTweet-
#ESCCongress #JACCHF LBCT SimPub: #Dapagliflozin is safe & improves outcomes irrespective of baseline NT-proBNP concentrations in #HFmrEF/#HFpEF, w/ the greatest absolute benefit likely seen in patients w/ higher NT-proBNP concentrations. https://t.co/H4mIJdoY9i #CardioTwitter https://t.co/capYyiSaFK
-
-
Mashup Score: 0
Skip to main content All TopicsTopics By JournalCollections JACC JACC: Advances JACC: Asia …
Source: www.jacc.orgCategories: Expert Picks, Latest HeadlinesTweet-
It's Day 2️⃣ of #ESCCongress! Today's hot line trials touch on REVIVED, ALL-HEART, DELIVER, & more! Learn more about these topics from our #JACCJournals clinical topic collections: https://t.co/ZEhsoCji4E #cvPrev #HFmrEF #IHD #HeartFailure #CardioTwitter #CVD https://t.co/nKVMgYbV1X
-
-
Mashup Score: 4DELIVER topline results: Dapagliflozin reduces CV death, worsening HF in EF more than 40% - 2 year(s) ago
Topline findings from the phase 3 DELIVER trial show dapagliflozin significantly reduced risk for CV death or worsening HF compared with placebo in adults HF with mildly reduced or preserved ejection fraction, AstraZeneca announced.The trial of the SGLT2 inhibitor dapagliflozin (Farxiga) was conducted in more than 6,000 patients with HF with mildly reduced or preserved EF, defined as left
Source: www.healio.comCategories: Cardiology News and Journals, Latest HeadlinesTweet-
Topline findings from the phase 3 #DELIVER trial show #dapagliflozin significantly reduced risk for CV death or worsening HF compared with placebo in adults #HFmrEF or #HFpEF @scottdsolomon @BrighamResearch #SGLT2i @EndocrineToday #CardioTwitter https://t.co/yVxJqrnGS6
-
In this short clip, Drs. @senthil_selv & @scottdsolomon summarize their newly published paper on #bloodpressure and #dapagliflozin in #HFmrEF or #HFpEF. 📃 #HFSA2022 #JACCHF LBCT paper: https://t.co/dGwJU0H74e #HeartFailure #DELIVER #CardioEd #CardioTwitter @BiykemB https://t.co/vFgVQD7wLu